Education · Major Section
GLP-1 medications have changed the landscape of obesity treatment. This page is a balanced, educational view from a metabolic surgeon — what the medications do, where surgery still has a role, and what long-term care actually requires.
Educational content. Not a substitute for individualized medical advice.
Author & medical reviewer
Written and clinically reviewed by Ariel Ortiz Lagardere, MD, FACS, FASMBS — Founder & Medical Director, Obesity Control Center®; Professor of Surgery, UABC.
Last reviewed: January 2026. Educational content only — see medical review policy and disclosures.
Educational schematic
A simplified view — not clinical guidance. Every patient is unique.
Overweight (BMI 25–29)
Primary care, nutrition, activity.
Class I obesity (BMI 30–34)
Pharmacotherapy often first-line.
Class II (BMI 35–39) + comorbidity
Combination strategies increasingly common.
Class III (BMI ≥ 40)
Metabolic surgery has the most durable outcome data.
After GLP-1 discontinuation with regain
Surgery is often the most durable next step.
01
Semaglutide and tirzepatide have demonstrated weight-loss outcomes in the 15–22% range — territory that previously belonged almost exclusively to bariatric surgery. That alone has reshaped the conversation. For the first time, an effective non-surgical option exists for many patients.
02
GLP-1 receptor agonists modulate appetite, satiety, gastric emptying, and glycemic control. They do not, by themselves, change the underlying biology of fat-mass regulation. When the medication is discontinued, the body's defended weight setpoint largely reasserts itself.
03
Pharmacotherapy is a first-line option for many patients with class I and class II obesity, an adjunct before or after surgery, and a critical tool for patients who are not surgical candidates or who decline surgery.
04
Surgery + medication strategies — typically a sleeve gastrectomy or bypass followed by GLP-1 maintenance — are an area of active research. Early signals suggest improved durability of weight loss and improved metabolic markers compared to either modality alone, though long-term trials are ongoing.
05
Many patients arrive at our clinic having lost significant weight on GLP-1 medication but unable to tolerate ongoing therapy — due to cost, side effects, or insurance changes. For these patients, metabolic surgery is often the most durable next step, and the preoperative weight loss is a clinical advantage.
06
Obesity is a chronic disease. GLP-1 medications, surgery, and behavioral support are all tools — none of them are cures. Patients deserve a clinical relationship that lasts decades, not weeks, and a treatment plan that adapts as their biology and circumstances change.
07
There is no single 'best' treatment. There is the best treatment for you, this year, given your biology, your tolerance, your access, and your goals. That decision deserves time, expertise, and honest conversation — not a one-size-fits-all algorithm.
08
Next-generation triple agonists, oral formulations, longer-duration injectables, and new combination protocols are all in advanced trials. The next five years will look very different from the last five. The principles, however — long-term follow-up, individualized care, and respect for the biology — will not change.
"There is no single best treatment. There is the best treatment for you, this year, given your biology, your tolerance, your access, and your goals."
Dr. Ariel Ortiz®
Frequently asked
For some patients, yes — particularly those with class I obesity or those who cannot undergo surgery. For patients with severe obesity, metabolic disease, or a need for durable weight loss without ongoing pharmacotherapy, surgery remains the most consistently effective treatment.
Often, yes. Preoperative weight loss on GLP-1 therapy can reduce operative risk, improve visualization, and give patients a psychological head start. The decision belongs to the treating team and should account for tolerance, cost, and timing.
This is an active area of clinical practice and research. Post-operative GLP-1 therapy may support durability of weight loss and improve metabolic markers in selected patients, particularly those with weight recurrence or inadequate response.
Published data consistently show that when GLP-1 medications are discontinued without another intervention, the body's defended weight setpoint reasserts itself and much of the lost weight returns over 12 to 24 months. This is not a personal failure — it is the underlying biology.
Surgery is worth discussing when medications are not tolerated, not accessible, not durable enough, or not sufficient for the degree of weight loss or metabolic improvement a patient needs. That decision is individual and belongs in a specialist evaluation.
Educational content only. Individual medical decisions require a qualified clinician.
For patient care
This site is a professional and educational resource. For patient care — consultations, scheduling, and surgery — please visit Obesity Control Center directly.
Visit Obesity Control Center ↗